U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07694622) titled 'Targeting MYC in High-Risk Medulloblastoma' on July 03.
Brief Summary: Medulloblastoma is the most common malignant brain tumor in children. Group 3 medulloblastoma (G3 MB) represents the most aggressive molecular subtype and is associated with poor prognosis, particularly in cases characterized by high expression or amplification of the MYC oncogene. Current treatment strategies are not tailored to this subgroup and are associated with significant long-term toxicities, highlighting the need for more specific therapeutic approaches.
This study aims to characterize biological processes and molecular pathways driven by high MYC expre...